title: Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR-TKI treatment.
abstract: Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is effective in lung cancer patients carrying sensitive EGFR mutations. In this study, we investigated if liver X receptor (LXR) agonist T0901317 could reverse the resistance of lung cancer cell lines A549 and H1650 to EGFR-TKI treatment. We found that T0901317 could make natural EGFR-TKI-resistant A549 human lung cancer cells sensitive to EGFR-TKI treatment and that this was dependent on LXRβ expression. However, T0901317 does not have a similar effect on another natural EGFR-TKI-resistant cell line H1650.
authors.affiliation: Research Center for Clinical Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Jiangsu Province China.
authors.forename: Haixia
authors.initials: H
authors.lastname: Cao
authors.affiliation: Research Center for Clinical Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Jiangsu Province China; Department of Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Jiangsu Province China.
authors.forename: Shaorong
authors.initials: S
authors.lastname: Yu
authors.affiliation: Research Center for Clinical Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Jiangsu Province China.
authors.forename: Dan
authors.initials: D
authors.lastname: Chen
authors.affiliation: Research Center for Clinical Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Jiangsu Province China.
authors.forename: Changwen
authors.initials: C
authors.lastname: Jing
authors.affiliation: Research Center for Clinical Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Jiangsu Province China.
authors.forename: Zhuo
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Research Center for Clinical Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Jiangsu Province China.
authors.forename: Rong
authors.initials: R
authors.lastname: Ma
authors.affiliation: Research Center for Clinical Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Jiangsu Province China.
authors.forename: Siwen
authors.initials: S
authors.lastname: Liu
authors.affiliation: The Fourth Clinical School of Nanjing Medical University Jiangsu Province China.
authors.forename: Jie
authors.initials: J
authors.lastname: Ni
authors.affiliation: Research Center for Clinical Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Jiangsu Province China; Department of Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Jiangsu Province China.
authors.forename: Jifeng
authors.initials: J
authors.lastname: Feng
authors.affiliation: Research Center for Clinical Oncology Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research Nanjing Medical University Affiliated Cancer Hospital Jiangsu Province China.
authors.forename: Jianzhong
authors.initials: J
authors.lastname: Wu
keywords: EGFR‐TKI; liver X receptors; lung cancer; resistance